Chronic Administration of the N-Methyl-D-Aspartate Receptor Antagonist Ketamine Improves Rett Syndrome Phenotype

Biological Psychiatry

Volumn 79, Issue 9, 2016, Pages 755-764

  Patrizi, Annarita ^a   Picard, Nathalie ^a   Simon, Alex Joseph ^a   Gunner, Georgia ^a   Centofante, Eleonora ^a   Andrews, Nick Arthur ^a   Fagiolini, Michela ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Behavior; Breathing; Cortical activity; Parvalbumin connectivity; Preclinical trial; Survival

Indexed keywords

KETAMINE; PARVALBUMIN; 4 AMINOBUTYRIC ACID RECEPTOR; MECP2 PROTEIN, MOUSE; METHYL CPG BINDING PROTEIN 2; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ACUTE DRUG ADMINISTRATION; ADULT; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; AREA UNDER THE CURVE RATIO; ARTICLE; BRAIN-TO-PLASMA RATIO; CHRONIC DRUG ADMINISTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; IN VIVO STUDY; LOCOMOTION; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MOTOR COORDINATION; MOTOR PERFORMANCE; MOUSE; NEUROTRANSMISSION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PREPULSE INHIBITION; PRIORITY JOURNAL; RETT SYNDROME; SINGLE DRUG DOSE; STARTLE REFLEX; TREATMENT OUTCOME; VISUAL CORTEX; VISUAL THRESHOLD; VOLUME OF DISTRIBUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BREATHING; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GENETICS; KNOCKOUT MOUSE; METABOLISM; NERVE CELL; PATHOPHYSIOLOGY; PHENOTYPE; PHOTOSTIMULATION; PHYSIOLOGY; PYRAMIDAL NERVE CELL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL ANALYSIS; VISUAL ACUITY;

ANIMALS; DISEASE MODELS, ANIMAL; GABAERGIC NEURONS; KETAMINE; METHYL-CPG-BINDING PROTEIN 2; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEURONS; PARVALBUMINS; PHENOTYPE; PHOTIC STIMULATION; PYRAMIDAL CELLS; RECEPTORS, N-METHYL-D-ASPARTATE; RESPIRATION; RETT SYNDROME; SURVIVAL ANALYSIS; VISUAL ACUITY; VISUAL CORTEX;

EID: 85028247263     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2015.08.018     Document Type: Article

References (73)

1. Hagberg, B., Clinical manifestations and stages of Rett syndrome. Ment Retard Dev Disabil Res Rev 8 (2001), 61–66.
2. Chahrour, M., Zoghbi, H.Y., The story of Rett syndrome: From clinic to neurobiology. Neuron 56 (2007), 422–437.
3. Katz, D.M., Dutschmann, M., Ramirez, J.M., Hilaire, G., Breathing disorders in Rett syndrome: Progressive neurochemical dysfunction in the respiratory network after birth. Respir Physiol Neurobiol 168 (2009), 101–108.
4. Neul, J.L., Kaufmann, W.E., Glaze, D.G., Christodoulou, J., Clarke, A.J., Bahi-Buisson, N., et al. Rett syndrome: Revised diagnostic criteria and nomenclature. Ann Neurol 68 (2010), 944–950.
5. Amir, R.E., Van den Veyver, I.B., Wan, M., Tran, C.Q., Francke, U., Zoghbi, H.Y., Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 23 (1999), 185–188.
6. Laurvick, C.L., de Klerk, N., Bower, C., Christodoulou, J., Ravine, D., Ellaway, C., et al. Rett syndrome in Australia: A review of the epidemiology. J Pediatr 148 (2006), 347–352.
7. Lyst, M.J., Bird, A., Rett syndrome: A complex disorder with simple roots. Nat Rev Genet 16 (2015), 261–274.
8. Chen, R.Z., Akbarian, S., Tudor, M., Jaenisch, R., Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet 27 (2001), 327–331.
9. Guy, J., Hendrich, B., Holmes, M., Martin, J.E., Bird, A., A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet 27 (2001), 322–326.
10. Asaka, Y., Jugloff, D.G.M., Zhang, L., Eubanks, J.H., Fitzsimonds, R.M., Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome. Neurobiol Dis 21 (2006), 217–227.
11. Guy, J., Gan, J., Selfridge, J., Cobb, S., Bird, A., Reversal of neurological defects in a mouse model of Rett syndrome. Science 315 (2007), 1143–1147.
12. Shepherd, G.M.G., Katz, D.M., Synaptic microcircuit dysfunction in genetic models of neurodevelopmental disorders: Focus on Mecp2 and Met. Curr Opin Neurobiol 21 (2011), 827–833.
13. Kron, M., Howell, C.J., Adams, I.T., Ransbottom, M., Christian, D., Ogier, M., Katz, D.M., Brain activity mapping in Mecp2 mutant mice reveals functional deficits in forebrain circuits, including key nodes in the default mode network, that are reversed with ketamine treatment. J Neurosci 32 (2012), 13860–13872.
14. Durand, S., Patrizi, A., Quast, K.B., Hachigian, L., Pavlyuk, R., Saxena, A., et al. NMDA receptor regulation prevents regression of visual cortical function in the absence of Mecp2. Neuron 76 (2012), 1078–1090.
15. Kline, D.D., Ogier, M., Kunze, D.L., Katz, D.M., Exogenous brain-derived neurotrophic factor rescues synaptic dysfunction in Mecp2-null mice. J Neurosci 30 (2010), 5303–5310.
16. Medrihan, L., Tantalaki, E., Aramuni, G., Sargsyan, V., Dudanova, I., Missler, M., Zhang, W., Early defects of GABAergic synapses in the brainstem of a MeCP2 mouse model of Rett syndrome. J Neurophysiol 99 (2007), 112–121.
17. Taneja, P., Ogier, M., Brooks-Harris, G., Schmid, D.A., Katz, D.M., Nelson, S.B., Pathophysiology of locus ceruleus neurons in a mouse model of Rett syndrome. J Neurosci 29 (2009), 12187–12195.
18. Zhang, L., He, J., Jugloff, D.G.M., Eubanks, J.H., The MeCP2-null mouse hippocampus displays altered basal inhibitory rhythms and is prone to hyperexcitability. Hippocampus 18 (2008), 294–309.
19. Calfa, G., Hablitz, J.J., Pozzo-Miller, L., Network hyperexcitability in hippocampal slices from Mecp2 mutant mice revealed by voltage-sensitive dye imaging. J Neurophysiol 105 (2011), 1768–1784.
20. Dani, V.S., Chang, Q., Maffei, A., Turrigiano, G.G., Jaenisch, R., Nelson, S.B., Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. Proc Natl Acad Sci U S A 102 (2005), 12560–12565.
21. Wood, L., Gray, N.W., Zhou, Z., Greenberg, M.E., Shepherd, G.M.G., Synaptic circuit abnormalities of motor-frontal layer 2/3 pyramidal neurons in an RNA interference model of methyl-CpG-binding protein 2 deficiency. J Neurosci 29 (2009), 12440–12448.
22. Wood, L., Shepherd, G.M.G., Synaptic circuit abnormalities of motor-frontal layer 2/3 pyramidal neurons in a mutant mouse model of Rett syndrome. Neurobiol Dis 38 (2010), 281–287.
23. Blue, M.E., Naidu, S., Johnston, M.V., Development of amino acid receptors in frontal cortex from girls with Rett syndrome. Ann Neurol 45 (1999), 541–545.
24. Blue, M.E., Naidu, S., Johnston, M.V., Altered development of glutamate and GABA receptors in the basal ganglia of girls with Rett syndrome. Exp Neurol 156 (1999), 345–352.
25. Blue, M.E., Kaufmann, W.E., Bressler, J., Eyring, C., O'driscoll, C., Naidu, S., Johnston, M.V., Temporal and regional alterations in NMDA receptor expression in Mecp2-null mice. Anat Rec (Hoboken) 294 (2011), 1624–1634.
26. Mierau, S., Patrizi, A., Hensch, T., Fagiolini, M., Cell-specific regulation of NMDA receptor maturation by MeCP2 in cortical circuits. Biol Psychiatry 79 (2016), 746–754.
27. Breier, A., Malhotra, A.K., Pinals, D.A., Weisenfeld, N.I., Pickar, D., Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am J Psychiatry 154 (1997), 805–811.
28. Jackson, M.E., Homayoun, H., Moghaddam, B., NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. Proc Natl Acad Sci U S A 101 (2004), 8467–8472.
29. Kinney, J.W., Davis, C.N., Tabarean, I., Conti, B., Bartfai, T., Behrens, M.M., A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons. J Neurosci 26 (2006), 1604–1615.
30. Behrens, M.M., Ali, S.S., Dao, D.N., Lucero, J., Shekhtman, G., Quick, K.L., Dugan, L.L., Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science 318 (2007), 1645–1647.
31. Fagiolini, M., Katagiri, H., Miyamoto, H., Mori, H., Grant, S.G.N., Mishina, M., Hensch, T.K., Separable features of visual cortical plasticity revealed by N-methyl-D-aspartate receptor 2A signaling. Proc Natl Acad Sci U S A 100 (2003), 2854–2859.
32. Prusky, G.T., Alam, N.M., Beekman, S., Douglas, R.M., Rapid quantification of adult and developing mouse spatial vision using a virtual optomotor system. Invest Ophthalmol Vis Sci 45 (2004), 4611–4616.
33. Zanella, S., Mebarek, S., Lajard, A.M., Picard, N., Dutschmann, M., Hilaire, G., Oral treatment with desipramine improves breathing and life span in Rett syndrome mouse model. Respir Physiol Neurobiol 160 (2008), 116–121.
34. Morgan, C.J.A., Curran, H.V., Ketamine use: A review. Addiction 107 (2012), 27–38.
35. Shaffer, C.L., Osgood, S.M., Smith, D.L., Liu, J., Trapa, P.E., Enhancing ketamine translational pharmacology via receptor occupancy normalization. Neuropharmacology 86 (2014), 174–180.
36. Rowland, L.M., Subanesthetic ketamine: How it alters physiology and behavior in humans. Aviat Space Environ Med 76 (2005), C52–C58.
37. Irifune, M., Shimizu, T., Nomoto, M., Ketamine-induced hyperlocomotion associated with alteration of presynaptic components of dopamine neurons in the nucleus accumbens of mice. Pharmacol Biochem Behav 40 (1991), 399–407.
38. Verma, A., Moghaddam, B., NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: Modulation by dopamine. J Neurosci 16 (1996), 373–379.
39. Cilia, J., Hatcher, P., Reavill, C., Jones, D.N.C., (+/-) Ketamine-induced prepulse inhibition deficits of an acoustic startle response in rats are not reversed by antipsychotics. J Psychopharmacol 21 (2007), 302–311.
40. Imre, G., Fokkema, D.S., Boer, J.A. Den, Ter Horst, G.J., Dose-response characteristics of ketamine effect on locomotion, cognitive function and central neuronal activity. Brain Res Bull 69 (2006), 338–345.
41. Braff, D.L., Geyer, M.A., Light, G.A., Sprock, J., Perry, W., Cadenhead, K.S., Swerdlow, N.R., Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr Res 49 (2001), 171–178.
42. Venâncio, C., Magalhães, A., Antunes, L., Summavielle, T., Impaired spatial memory after ketamine administration in chronic low doses. Curr Neuropharmacol 9 (2011), 251–255.
43. Wang, C., Zheng, D., Xu, J., Lam, W., Yew, D.T., Brain damages in ketamine addicts as revealed by magnetic resonance imaging. Front Neuroanat, 7, 2013, 23.
44. Weng, S.M., McLeod, F., Bailey, M.E.S., Cobb, S.R., Synaptic plasticity deficits in an experimental model of rett syndrome: Long-term potentiation saturation and its pharmacological reversal. Neuroscience 180 (2011), 314–321.
45. Auerbach, W., Hurlbert, M.S., Hilditch-Maguire, P., Wadghiri, Y.Z., Wheeler, V.C., Cohen, S.I., et al. The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. Hum Mol Genet 10 (2001), 2515–2523.
46. Viemari, J.-C., Roux, J.-C., Tryba, A.K., Saywell, V., Burnet, H., Peña, F., et al. Mecp2 deficiency disrupts norepinephrine and respiratory systems in mice. J Neurosci 25 (2005), 11521–11530.
47. Russell, V.A., Oades, R.D., Tannock, R., Killeen, P.R., Auerbach, J.G., Johansen, E.B., Sagvolden, T., Response variability in attention-deficit/hyperactivity disorder: A neuronal and glial energetics hypothesis. Behav Brain Funct, 2, 2006, 30.
48. Jeevakumar, V., Kroener, S., Ketamine administration during the second postnatal week alters synaptic properties of fast-spiking interneurons in the medial prefrontal cortex of adult mice. Cereb Cortex 26 (2016), 1117–1129.
49. Tomassy, G.S., Morello, N., Calcagno, E., Giustetto, M., Developmental abnormalities of cortical interneurons precede symptoms onset in a mouse model of Rett syndrome. J Neurochem 131 (2014), 115–127.
50. Hensch, T.K., Critical period plasticity in local cortical circuits. Nat Rev Neurosci 6 (2005), 877–888.
51. Sleigh, J., Harvey, M., Voss, L., Denny, B., Ketamine - more mechanisms of action than just NMDA blockade. Trends Anaesth Crit Care 4 (2014), 76–81.
52. Moaddel, R., Abdrakhmanova, G., Kozak, J., Jozwiak, K., Toll, L., Jimenez, L., et al. Sub-anesthetic concentrations of (R,S)-ketamine metabolites inhibit acetylcholine-evoked currents in α7 nicotinic acetylcholine receptors. Eur J Pharmacol 698 (2013), 228–234.
53. Yamakura, T., Chavez-Noriega, L.E., Harris, R.A., Subunit-dependent inhibition of human neuronal nicotinic acetylcholine receptors and other ligand-gated ion channels by dissociative anesthetics ketamine and dizocilpine. Anesthesiology 92 (2000), 1144–1153.
54. Craft, J.B., Coaldrake, L.A., Yonekura, M.L., Dao, S.D., Co, E.G., Roizen, M.F., et al. Ketamine, catecholamines, and uterine tone in pregnant ewes. Am J Obstet Gynecol 146 (1983), 429–434.
55. Ebert, B., Mikkelsen, S., Thorkildsen, C., Borgbjerg, F.M., Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 333 (1997), 99–104.
56. Mealing, G.A., Lanthorn, T.H., Murray, C.L., Small, D.L., Morley, P., Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block. J Pharmacol Exp Ther 288 (1999), 204–210.
57. Tseng, K.Y., O'Donnell, P., Dopamine modulation of prefrontal cortical interneurons changes during adolescence. Cereb Cortex 17 (2007), 1235–1240.
58. Homayoun, H., Moghaddam, B., NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27 (2007), 11496–11500.
59. Chattopadhyaya, B., Di Cristo, G., Higashiyama, H., Knott, G.W., Kuhlman, S.J., Welker, E., Huang, Z.J., Experience and activity-dependent maturation of perisomatic GABAergic innervation in primary visual cortex during a postnatal critical period. J Neurosci 24 (2004), 9598–9611.
60. Sugiyama, S., Di Nardo, A.A., Aizawa, S., Matsuo, I., Volovitch, M., Prochiantz, A., Hensch, T.K., Experience-dependent transfer of Otx2 homeoprotein into the visual cortex activates postnatal plasticity. Cell 134 (2008), 508–520.
61. Kuczewski, N., Porcher, C., Gaiarsa, J.-L., Activity-dependent dendritic secretion of brain-derived neurotrophic factor modulates synaptic plasticity. Eur J Neurosci 32 (2010), 1239–1244.
62. Miller, O.H., Yang, L., Wang, C.-C., Hargroder, E.A., Zhang, Y., Delpire, E., Hall, B.J., GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. Elife 3 (2014), 1–22.
63. Naughton, M., Clarke, G., Oleary, O.F., Cryan, J.F., Dinan, T.G., A review of ketamine in affective disorders: Current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action. J Affect Disord 156 (2014), 24–35.
64. Autry, A.E., Adachi, M., Nosyreva, E., Na, E.S., Los, M.F., Cheng, P., et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475 (2011), 91–95.
65. Duncan, W.C., Sarasso, S., Ferrarelli, F., Selter, J., Riedner, B.A., Hejazi, N.S., et al. Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol 16 (2012), 301–311.
66. Kavalali, E.T., Monteggia, L.M., Synaptic mechanisms underlying rapid antidepressant action of ketamine. Am J Psychiatry 169 (2012), 1150–1156.
67. Ricciardi, S., Boggio, E.M., Grosso, S., Lonetti, G., Forlani, G., Stefanelli, G., et al. Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. Hum Mol Genet 20 (2011), 1182–1196.
68. Li, W., Pozzo-Miller, L., BDNF deregulation in Rett syndrome. Neuropharmacology 76 (2014), 737–746.
69. Gideons, E.S., Kavalali, E.T., Monteggia, L.M., Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci U S A 111 (2014), 8649–8654.
70. Kotermanski, S.E., Wood, J.T., Johnson, J.W., Memantine binding to a superficial site on NMDA receptors contributes to partial trapping. J Physiol 587 (2009), 4589–4604.
71. Zhou, X., Hollern, D., Liao, J., Andrechek, E., Wang, H., NMDA receptor-mediated excitotoxicity depends on the coactivation of synaptic and extrasynaptic receptors. Cell Death Dis, 4, 2013, e560.
72. Ko, H., Cossell, L., Baragli, C., Antolik, J., Clopath, C., Hofer, S.B., Mrsic-Flogel, T.D., The emergence of functional microcircuits in visual cortex. Nature 496 (2013), 96–100.
73. Gadalla, K.K.E., Ross, P.D., Riddell, J.S., Bailey, M.E.S., Cobb, S.R., Gait analysis in a Mecp2 knockout mouse model of Rett syndrome reveals early-onset and progressive motor deficits. PLoS One, 9, 2014, e112889.